| Identification | More | [Name]
Difluoxacin hydrochloride | [CAS]
91296-86-5 | [Synonyms]
6-FLUORO-1-(4-FLUOROPHENYL)-1,4-DIHYDRO-7-(4-METHYLPIPERAZINO)-4-OXO-3-QUINOLINECARBOXYLIC ACID HYDROCHLORIDE
DIFLOXACIN HCL
DIFLOXACIN HYDROCHLORIDE
DIFLUOXACIN HYDROCHLORIDE
VETRANAL
Difluoxacin HCL
3-Quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-, monohydrochloride
6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid hydrochloride
6-Fluoro-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid hydrochloride | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C21H20ClF2N3O3 | [MDL Number]
MFCD03840489 | [Molecular Weight]
435.85 | [MOL File]
91296-86-5.mol |
| Chemical Properties | Back Directory | [Melting point ]
>245°C (dec.) | [storage temp. ]
0-6°C | [solubility ]
Soluble in aqueous buffer | [form ]
powder | [color ]
White to off-white | [InChI]
InChI=1S/C21H19F2N3O3.ClH/c1-24-6-8-25(9-7-24)19-11-18-15(10-17(19)23)20(27)16(21(28)29)12-26(18)14-4-2-13(22)3-5-14;/h2-5,10-12H,6-9H2,1H3,(H,28,29);1H | [InChIKey]
JFMGBGLSDVIOHL-UHFFFAOYSA-N | [SMILES]
C12C=C(C(F)=CC=1C(C(C(=O)O)=CN2C1=CC=C(F)C=C1)=O)N1CCN(C)CC1.Cl | [CAS DataBase Reference]
91296-86-5(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Difloxacin is a fluoroquinolone antibiotic.1 It is active against isolates of anaerobic bacteria, including B. fragilis, as well as Fusobacterium and Actinomyces species with MIC values ranging from ≤0.125 to 8 μg/ml. It eliminates E. coli and B. fragilis infection in a rat intra-abdominal abscess model when administered at a dose of 40 mg/kg three times per day.2 | [Chemical Properties]
Off-White to Pale Yellow Solid | [Uses]
A fluoroquinolone antibacterial structurally related to norfloxacin. | [Uses]
A quinolone antibacterial compound. Structurally related to norfloxacin | [Uses]
antibacterial, DNA gyrase inhibitor | [References]
[1] M B BANSAL H T. Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitro.[J]. Antimicrobial Agents and Chemotherapy, 1987, 31 4: 619-621. DOI: 10.1128/aac.31.4.619
[2] H THADEPALLI S K C S V Gollapudi. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.[J]. Antimicrobial Agents and Chemotherapy, 1986, 30 4: 574-576. DOI: 10.1128/aac.30.4.574 |
|
|